<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439177</url>
  </required_header>
  <id_info>
    <org_study_id>OPM-G-V-1503</org_study_id>
    <nct_id>NCT02439177</nct_id>
  </id_info>
  <brief_title>Evaluating System Accuracy and User Performance of Omnitest® Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus</brief_title>
  <official_title>Evaluating System Accuracy and User Performance of Omnitest® Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the System Accuracy and User Performance evaluation of&#xD;
      the mentioned BGM systems by gaining a sufficient amount of measured data from capillary&#xD;
      blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>System accuracy, results obtained from fingertip using blood glucose monitoring systems compared to a reference equipment</measure>
    <time_frame>up to 7 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>User Performance of blood glucose monitoring system indicated by patient</measure>
    <time_frame>up to 7 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Omnitest 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood glucose monitoring system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omnitest 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood glucose monitoring system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood glucose monitoring system (Omnitest 3)</intervention_name>
    <arm_group_label>Omnitest 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood glucose monitoring system (Omnitest 5)</intervention_name>
    <arm_group_label>Omnitest 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects with type 1 or type 2 diabetes, for the evaluation of System&#xD;
             Accuracy also healthy subjects&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Signed and dated informed consent form&#xD;
&#xD;
          -  For small modifications of the insulin doses to achieve certain blood glucose values&#xD;
             (System Accuracy evaluation): Male or female subjects with diabetes mellitus type 1&#xD;
             with intensified insulin therapy (intensified conventional therapy - I.C.T.) or&#xD;
             insulin pump therapy (continuous subcutaneous insulin infusion - C.S.I.I.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Severe acute illness that, in the opinion of the investigating physician, might&#xD;
             confound the results of the test or which could result in a risk to the subject caused&#xD;
             by the test.&#xD;
&#xD;
          -  Severe chronic illness besides Diabetes mellitus as assessed by the investigating&#xD;
             physician that might confound the results of the test or which could result in a risk&#xD;
             to the subject caused by the test.&#xD;
&#xD;
          -  Mental incapacity or language barriers precluding adequate compliance with the test&#xD;
             procedures&#xD;
&#xD;
          -  Legal incompetence or limited legal competence&#xD;
&#xD;
          -  Dependency from the Sponsor or the clinical Investigator (e.g. co-workers of the&#xD;
             Sponsor or the clinical research centre)&#xD;
&#xD;
          -  For User Performance evaluation: Subjects having participated in a study with&#xD;
             Omnitest® 5 before.&#xD;
&#xD;
          -  For System Accuracy evaluation: subjects intended to provide blood samples with&#xD;
             glucose concentrations between 50 and 80 mg/dl must not have coronary heart disease,&#xD;
             myocardial infarction in history, cerebral events in history, peripheral artery&#xD;
             occlusive disease or impaired hypoglycaemia awareness&#xD;
&#xD;
          -  Anamnestically relevant amounts of interfering substances in the blood, following&#xD;
             labelling in the instructions for use as reviewed and evaluated by a physician during&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood glucose monitoring system</keyword>
  <keyword>System Accuracy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

